Novartis Deepens Strategic Collaboration with Boao Lecheng to Accelerate Real-World Evidence Research and Clinical Drug Development

2022Year10Month28Today, Novartis announced a further upgrade to its strategic cooperation with the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, establishing the Novartis Hainan Office and Real-World Research Center.Promote cooperation and exchange in real-world research and clinical drug development, while advancing the implementation of translational medicine in Hainan and the cultivation of relevant talents., while accelerating the availability of more innovative drugs to benefit patients in China as soon as possible, it also supports the development of China's healthcare industry.

Novartis Hainan Office and Real-World Research Center Inaugurated by Both Parties

Novartis was one of the earliest multinational pharmaceutical companies to cooperate with the Boao Lecheng Pilot Zone, and currently has6An innovative overseas special drug has landed in Boao Lecheng. The establishment of the Novartis Hainan Office and Real-World Research Center marks a new milestone in the cooperation between Novartis and Boao Lecheng.

President of Novartis Group (China), Daniel Brindle (Dan Brindle) Indicates:“Novartis is committed to working with all parties to accelerate the introduction of innovative drugs and improve drug accessibility. Boao Lecheng is one of Novartis' important partners in its innovation journey in China. Relying on this upgraded strategic cooperation, Novartis will continue to fully support Boao Lecheng's pilot initiatives and related innovative attempts in China, further accelerating the introduction of more overseas innovative specialty drugs into China for the benefit of Chinese patients. At the same time, Novartis will also vigorously boost the enhancement of China's pharmaceutical innovation capabilities, contributing from more levels.‘Healthy China2030’And‘The 14th Five-Year Plan for National Health in China’Contribute strength.”

In recent years, thanks to the people-oriented policies promoted by the state and Hainan, such as medical tourism and innovative payment methods, the number of special drugs and medical devices introduced into Boao Lecheng, as well as the number of patients using these special drugs and devices, has continued to increase. For example, Novartis' small interfering RNA therapy (siRNA) Lipid-lowering innovative drugInclisiranFor example, since2021Year7Since its introduction to Boao Lecheng in the past month, thousands of patients have actively sought this therapy and received treatment under the guidance of doctors, highlighting a significant clinical demand.

Jia Ning, Director of the Administration Bureau of Boao Lecheng International Medical Tourism Pilot Zone in Hainan, stated:“Very pleased that the Novartis Hainan office has successfully landed in the Pilot Zone. Overseas special drugs in the Pilot Zone‘Pilot first’To date, the development of becoming a health hallmark for patients in the province and even throughout China, fulfilling urgent treatment needs, cannot be achieved without the support of cooperative enterprises. Lecheng will continue to optimize its business environment, encourage innovation, and empower more innovative opportunities for partner companies. It is hoped that Novartis can introduce more and better innovative solutions to Lecheng, helping it further enhance the level of medical services, and allowing more Chinese patients to access the most advanced treatments worldwide.”

Novartis was one of the earliest multinational pharmaceutical companies to support Boao Lecheng.2018Year8Month, Boao Super Hospital was established less than5In just a few months, Novartis's Cosentyx, which had not yet been launched in China, arrived.^®The first injection. Subsequently, both parties2020And2021Signed strategic cooperation memorandums consecutively at the China International Import Expo, joining hands to accelerate the introduction of global new products and technologies into China. They are also cooperating in areas such as promoting the exchange of diagnosis and treatment experiences in the field of major disease therapies, advancing the construction of a real-world data research system, supporting innovative medical research and talent cultivation, and enhancing international communication and collaboration. Currently, there are...6Novartis Innovative Drug Lands in Boao Lecheng,8Novartis' innovative drug included in Boao Lecheng Global Special Drug Insurance.

Novartis is committed to working with all parties in China's medical ecosystem to promote innovation, introduce innovation, and bring health to the people of China.1987Since the year, Novartis has had nearly90An innovative drug has been approved in China, ranking among the top in multinational pharmaceutical companies. Focusing on disease areas with unmet medical needs, Novartis continues to accelerate the introduction and launch of innovative drugs, planning to submit applications in China within five years.50Applications for new drugs and new indications. The deepening cooperation between Novartis and Boao Lecheng will help benefit Chinese patients faster and better.